WD
WDH1.F Demant A/S
- Market cap
- EUR 9.56B
- P/E
- 29.4x
- P/B
- 6.95x
- ROE
- 15.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is WDH1.F undervalued?
Graham numberThe Graham number of Demant A/S cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Demant A/S fundamental analysis
No fundamental analysis for Demant A/S yet.
Demant A/S stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Demant A/S
Demant A/S operates as a hearing healthcare company in Europe, North America, Asia, Pacific region, and internationally. It engages in the development, manufacture, and wholesale of hearing aids; owning and operating hearing care clinics; and offers hearing and balance assessment solutions used by audiologists, ENT doctors, and balance clinics. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founde…
Full company profileDemant A/S financial statements
Demant A/S annual financial statements (DKK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 12.0B | 13.2B | 13.9B | 14.9B | 14.5B | 18.4B | 19.7B | 21.6B | 22.4B | 23.0B |
| Gross Profit | 9.03B | 10.0B | 10.8B | 11.3B | 10.2B | 13.8B | 14.7B | 16.3B | 17.1B | 17.4B |
| Operating Income | 1.86B | 2.29B | 2.40B | 2.03B | 1.03B | 3.33B | 3.09B | 4.44B | 4.31B | 3.92B |
| EBITDA | - | 2.70B | 2.91B | 3.03B | 2.50B | 4.44B | 4.30B | 5.57B | 5.80B | 5.17B |
| Net Income | 1.46B | 1.75B | 1.82B | 1.46B | 1.12B | 2.51B | 2.08B | 1.80B | 2.39B | 1.55B |
| EPS | - | 6.94 | 7.43 | 6.08 | 4.67 | 11 | 9.33 | 8.14 | 11 | 7.33 |
| Balance Sheet | ||||||||||
| Total Assets | 15.5B | 16.2B | 17.9B | 21.8B | 21.9B | 24.9B | 29.9B | 30.5B | 32.5B | 39.1B |
| Total Liabilities | 8.58B | 8.79B | 10.9B | 14.2B | 13.6B | 16.9B | 21.3B | 21.2B | 22.8B | 29.2B |
| Shareholders' Equity | 6.96B | 7.43B | 7.05B | 7.64B | 8.25B | 7.98B | 8.56B | 9.26B | 9.56B | 9.84B |
| Cash & Short-term Investments | 710M | 697M | 630M | 792M | 952M | 1.17B | 1.13B | 1.14B | 1.11B | 1.33B |
| Cash Flow | ||||||||||
| Operating Cash Flow | 1.68B | 1.87B | 1.68B | 2.15B | 2.62B | 3.28B | 2.37B | 4.34B | 4.08B | 3.85B |
| Capital Expenditure | 471M | 312M | 429M | 571M | 507M | 562M | 647M | 846M | 779M | 857M |
| Free Cash Flow | - | 1.43B | 1.07B | 1.38B | 1.94B | 2.55B | 1.70B | 3.49B | 3.30B | 3.00B |
| Ratios | ||||||||||
| ROE | 21.0% | 23.6% | 25.9% | 19.1% | 13.6% | 31.5% | 24.3% | 19.4% | 25.0% | 15.7% |
| ROA | 9.4% | 10.8% | 10.2% | 6.7% | 5.1% | 10.1% | 7.0% | 5.9% | 7.4% | 4.0% |
| Net Profit Margin | 12.2% | 13.3% | 13.1% | 9.8% | 7.7% | 13.7% | 10.6% | 8.3% | 10.6% | 6.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Demant A/S dividends
Demant A/S has not paid dividends in the last 10 fiscal years.
Last stock split: 5:1 on May 25, 2016.
Who owns Demant A/S
- Insiders 60.00%
- Institutions 18.92%
- Public & others 21.08%
- Shares outstanding 211M
- Free float 83.8M
Demant A/S company profile
- Company name
- Demant A/S
- Ticker
- WDH1.F
- ISIN
- DK0060738599
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 26,616
- Fiscal year end
- December
- Address
- Kongebakken 9, Smørum, Denmark, 2765
- Phone
- 45 39 17 73 00
- Website
- demant.com
About Demant A/S
Demant A/S operates as a hearing healthcare company in Europe, North America, Asia, Pacific region, and internationally. It engages in the development, manufacture, and wholesale of hearing aids; owning and operating hearing care clinics; and offers hearing and balance assessment solutions used by audiologists, ENT doctors, and balance clinics. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark.
Demant A/S management
10- Mr. Søren NielsenCEO, President & Member of Executive Board · born 1970
- Mr. René Schneider M.ScCFO, President of Group Services & Member of Executive Board · born 1973
- Mr. Niels WagnerPresident of Hearing Care & Member of Executive Board · born 1971
- Sara Munch AndersenHead of Group Privacy & Compliance
- Stine BrandenhofGroup General Counsel
- Ms. Trine Kromann-MikkelsenVice President of Corporate Communication and Sustainability
- Mr. Peter PudselykkeHead of Investor Relations (Leave of Absence)
- Ms. Anne-Karen HuntPresident of Diagnostics Business Area · born 1977
- Mr. Bassel RifaiPresident of Hearing Aids Business Area · born 1982
- Gustav Kallehave HoeghInvestor Relations Officer